Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.0

the EACS Governing Board

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: The European AIDS Clinical Society (EACS) Guidelines have since 2005 provided multidisciplinary recommendations for the care of HIV-positive persons in geographically diverse areas. Guideline highlights: Major revisions have been made in all sections of the 2017 Guidelines: antiretroviral treatment (ART), comorbidities, coinfections and opportunistic diseases. Newly added are also a summary of the main changes made, and direct video links to the EACS online course on HIV Management. Recommendations on the clinical situations in which tenofovir alafenamide may be considered over tenofovir disoproxil fumarate are provided, and recommendations on which antiretrovirals can be used safely during pregnancy have been revised. Renal and bone toxicity and hepatitis C virus (HCV) treatment have been added as potential reasons for ART switches in fully virologically suppressed individuals, and dolutegravir/rilpivirine has been included as a treatment option. In contrast, dolutegravir monotherapy is not recommended. New recommendations on non-alcoholic fatty liver disease, chronic lung disease, solid organ transplantation, and prescribing in elderly are included, and human papilloma virus (HPV) vaccination recommendations have been expanded. All drug–drug interaction tables have been updated and new tables are included. Treatment options for direct-acting antivirals (DAAs) have been updated and include the latest combinations of sofosbuvir/velpatasvir/voxilaprevir and glecaprevir/pibrentasvir. Recommendations on management of DAA failure and acute HCV infection have been expanded. For treatment of tuberculosis (TB), it is underlined that intermittent treatment is contraindicated, and for resistant TB new data suggest that using a three-drug combination may be as effective as a five-drug regimen, and may reduce treatment duration from 18-24 to 6-10 months. Conclusions: Version 9.0 of the EACS Guidelines provides a holistic approach to HIV care and is translated into the six most commonly spoken languages.

Original languageEnglish
Pages (from-to)309-315
Number of pages7
JournalHIV Medicine
Volume19
Issue number5
DOIs
Publication statusPublished - May 1 2018

Fingerprint

Acquired Immunodeficiency Syndrome
HIV
Guidelines
Rilpivirine
Tenofovir
Therapeutics
Papillomaviridae
Hepacivirus
Antiviral Agents
Tuberculosis
Organ Transplantation
Virus Diseases
Drug Combinations
Coinfection
Lung Diseases
Comorbidity
Vaccination
Chronic Disease
Language
Kidney

Keywords

  • antiretroviral treatment
  • ART
  • coinfections
  • comorbidities
  • European AIDS Clinical Society guidelines
  • HBV
  • HCV
  • HIV
  • opportunistic diseases

ASJC Scopus subject areas

  • Health Policy
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.0. / the EACS Governing Board.

In: HIV Medicine, Vol. 19, No. 5, 01.05.2018, p. 309-315.

Research output: Contribution to journalArticle

@article{0245441219a44ad190a55fee1444dad7,
title = "Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.0",
abstract = "Background: The European AIDS Clinical Society (EACS) Guidelines have since 2005 provided multidisciplinary recommendations for the care of HIV-positive persons in geographically diverse areas. Guideline highlights: Major revisions have been made in all sections of the 2017 Guidelines: antiretroviral treatment (ART), comorbidities, coinfections and opportunistic diseases. Newly added are also a summary of the main changes made, and direct video links to the EACS online course on HIV Management. Recommendations on the clinical situations in which tenofovir alafenamide may be considered over tenofovir disoproxil fumarate are provided, and recommendations on which antiretrovirals can be used safely during pregnancy have been revised. Renal and bone toxicity and hepatitis C virus (HCV) treatment have been added as potential reasons for ART switches in fully virologically suppressed individuals, and dolutegravir/rilpivirine has been included as a treatment option. In contrast, dolutegravir monotherapy is not recommended. New recommendations on non-alcoholic fatty liver disease, chronic lung disease, solid organ transplantation, and prescribing in elderly are included, and human papilloma virus (HPV) vaccination recommendations have been expanded. All drug–drug interaction tables have been updated and new tables are included. Treatment options for direct-acting antivirals (DAAs) have been updated and include the latest combinations of sofosbuvir/velpatasvir/voxilaprevir and glecaprevir/pibrentasvir. Recommendations on management of DAA failure and acute HCV infection have been expanded. For treatment of tuberculosis (TB), it is underlined that intermittent treatment is contraindicated, and for resistant TB new data suggest that using a three-drug combination may be as effective as a five-drug regimen, and may reduce treatment duration from 18-24 to 6-10 months. Conclusions: Version 9.0 of the EACS Guidelines provides a holistic approach to HIV care and is translated into the six most commonly spoken languages.",
keywords = "antiretroviral treatment, ART, coinfections, comorbidities, European AIDS Clinical Society guidelines, HBV, HCV, HIV, opportunistic diseases",
author = "{the EACS Governing Board} and L. Ryom and C. Boesecke and M. Bracchi and J. Ambrosioni and A. Pozniak and J. Arribas and G. Behrens and Mallon, {P. G.M.} and M. Puoti and A. Rauch and Miro, {J. M.} and O. Kirk and C. Marzolini and Lundgren, {J. D.} and M. Battegay and {d'Arminio Monforte}, Antonella and Nathan Clumeck and Nikos Dedes and Gatell, {Jos{\'e} M.} and Andrzej Horban and Christine Katlama and Sheena McCormack and Molina, {Jean Michel} and Cristina Mussini and Fran{\cc}ois Raffi and Peter Reiss and Stellbrink, {Hans J{\"u}rgen} and Mark Bower and Paola Cinque and Simon Collins and Juliet Compston and {De Wit}, St{\'e}phane and Fabbri, {Leonardo M.} and Fux, {Christoph A.} and Giovanni Guaraldi and Esteban Mart{\'i}nez and Socrates Papapoulos and {du Pasquier}, Renaud and Neil Poulter and Ian Williams and Alan Winston and Juan Berenguer and Sanjay Bhagani and Raffaele Bruno and Svilen Konov and Karine Lacombe and Stefan Mauss and Lu{\'i}s Mend{\~a}o and Lars Peters and Rockstroh, {J{\"u}rgen K.}",
year = "2018",
month = "5",
day = "1",
doi = "10.1111/hiv.12600",
language = "English",
volume = "19",
pages = "309--315",
journal = "HIV Medicine",
issn = "1464-2662",
publisher = "Blackwell Publishing Ltd",
number = "5",

}

TY - JOUR

T1 - Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.0

AU - the EACS Governing Board

AU - Ryom, L.

AU - Boesecke, C.

AU - Bracchi, M.

AU - Ambrosioni, J.

AU - Pozniak, A.

AU - Arribas, J.

AU - Behrens, G.

AU - Mallon, P. G.M.

AU - Puoti, M.

AU - Rauch, A.

AU - Miro, J. M.

AU - Kirk, O.

AU - Marzolini, C.

AU - Lundgren, J. D.

AU - Battegay, M.

AU - d'Arminio Monforte, Antonella

AU - Clumeck, Nathan

AU - Dedes, Nikos

AU - Gatell, José M.

AU - Horban, Andrzej

AU - Katlama, Christine

AU - McCormack, Sheena

AU - Molina, Jean Michel

AU - Mussini, Cristina

AU - Raffi, François

AU - Reiss, Peter

AU - Stellbrink, Hans Jürgen

AU - Bower, Mark

AU - Cinque, Paola

AU - Collins, Simon

AU - Compston, Juliet

AU - De Wit, Stéphane

AU - Fabbri, Leonardo M.

AU - Fux, Christoph A.

AU - Guaraldi, Giovanni

AU - Martínez, Esteban

AU - Papapoulos, Socrates

AU - du Pasquier, Renaud

AU - Poulter, Neil

AU - Williams, Ian

AU - Winston, Alan

AU - Berenguer, Juan

AU - Bhagani, Sanjay

AU - Bruno, Raffaele

AU - Konov, Svilen

AU - Lacombe, Karine

AU - Mauss, Stefan

AU - Mendão, Luís

AU - Peters, Lars

AU - Rockstroh, Jürgen K.

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Background: The European AIDS Clinical Society (EACS) Guidelines have since 2005 provided multidisciplinary recommendations for the care of HIV-positive persons in geographically diverse areas. Guideline highlights: Major revisions have been made in all sections of the 2017 Guidelines: antiretroviral treatment (ART), comorbidities, coinfections and opportunistic diseases. Newly added are also a summary of the main changes made, and direct video links to the EACS online course on HIV Management. Recommendations on the clinical situations in which tenofovir alafenamide may be considered over tenofovir disoproxil fumarate are provided, and recommendations on which antiretrovirals can be used safely during pregnancy have been revised. Renal and bone toxicity and hepatitis C virus (HCV) treatment have been added as potential reasons for ART switches in fully virologically suppressed individuals, and dolutegravir/rilpivirine has been included as a treatment option. In contrast, dolutegravir monotherapy is not recommended. New recommendations on non-alcoholic fatty liver disease, chronic lung disease, solid organ transplantation, and prescribing in elderly are included, and human papilloma virus (HPV) vaccination recommendations have been expanded. All drug–drug interaction tables have been updated and new tables are included. Treatment options for direct-acting antivirals (DAAs) have been updated and include the latest combinations of sofosbuvir/velpatasvir/voxilaprevir and glecaprevir/pibrentasvir. Recommendations on management of DAA failure and acute HCV infection have been expanded. For treatment of tuberculosis (TB), it is underlined that intermittent treatment is contraindicated, and for resistant TB new data suggest that using a three-drug combination may be as effective as a five-drug regimen, and may reduce treatment duration from 18-24 to 6-10 months. Conclusions: Version 9.0 of the EACS Guidelines provides a holistic approach to HIV care and is translated into the six most commonly spoken languages.

AB - Background: The European AIDS Clinical Society (EACS) Guidelines have since 2005 provided multidisciplinary recommendations for the care of HIV-positive persons in geographically diverse areas. Guideline highlights: Major revisions have been made in all sections of the 2017 Guidelines: antiretroviral treatment (ART), comorbidities, coinfections and opportunistic diseases. Newly added are also a summary of the main changes made, and direct video links to the EACS online course on HIV Management. Recommendations on the clinical situations in which tenofovir alafenamide may be considered over tenofovir disoproxil fumarate are provided, and recommendations on which antiretrovirals can be used safely during pregnancy have been revised. Renal and bone toxicity and hepatitis C virus (HCV) treatment have been added as potential reasons for ART switches in fully virologically suppressed individuals, and dolutegravir/rilpivirine has been included as a treatment option. In contrast, dolutegravir monotherapy is not recommended. New recommendations on non-alcoholic fatty liver disease, chronic lung disease, solid organ transplantation, and prescribing in elderly are included, and human papilloma virus (HPV) vaccination recommendations have been expanded. All drug–drug interaction tables have been updated and new tables are included. Treatment options for direct-acting antivirals (DAAs) have been updated and include the latest combinations of sofosbuvir/velpatasvir/voxilaprevir and glecaprevir/pibrentasvir. Recommendations on management of DAA failure and acute HCV infection have been expanded. For treatment of tuberculosis (TB), it is underlined that intermittent treatment is contraindicated, and for resistant TB new data suggest that using a three-drug combination may be as effective as a five-drug regimen, and may reduce treatment duration from 18-24 to 6-10 months. Conclusions: Version 9.0 of the EACS Guidelines provides a holistic approach to HIV care and is translated into the six most commonly spoken languages.

KW - antiretroviral treatment

KW - ART

KW - coinfections

KW - comorbidities

KW - European AIDS Clinical Society guidelines

KW - HBV

KW - HCV

KW - HIV

KW - opportunistic diseases

UR - http://www.scopus.com/inward/record.url?scp=85045475030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045475030&partnerID=8YFLogxK

U2 - 10.1111/hiv.12600

DO - 10.1111/hiv.12600

M3 - Article

VL - 19

SP - 309

EP - 315

JO - HIV Medicine

JF - HIV Medicine

SN - 1464-2662

IS - 5

ER -